Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia.

COVID-19 antibody chronic lymphocytic leukemia kidney transplant vaccine

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
23 Sep 2021
Historique:
received: 31 08 2021
revised: 15 09 2021
accepted: 16 09 2021
entrez: 26 10 2021
pubmed: 27 10 2021
medline: 27 10 2021
Statut: epublish

Résumé

The impact of a third dose of COVID-19 vaccine on antibody responses is unclear in immunocompromised patients. The objective of this retrospective study was to characterize antibody responses induced by a third dose of mRNA COVID-19 vaccine in 160 kidney transplant recipients and 20 patients treated for chronic lymphocytic leukemia (CLL). Prevalence of anti-spike IgG ≥ 7.1 and ≥ 30 BAU/mL after the third dose were 47% (75/160) and 39% (63/160) in kidney transplant recipients, and 57% (29/51) and 50% (10/20) in patients treated for CLL. Longitudinal follow-up identified a moderate increase in SARS-CoV-2 anti-spike IgG levels after a third dose of vaccine in kidney transplant recipients (0.19 vs. 5.28 BAU/mL,

Identifiants

pubmed: 34696163
pii: vaccines9101055
doi: 10.3390/vaccines9101055
pmc: PMC8539204
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Viruses. 2021 Mar 05;13(3):
pubmed: 33807957
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
JAMA. 2021 Jul 23;:
pubmed: 34297036
Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353
pubmed: 34337100
Leukemia. 2021 Sep;35(9):2703-2705
pubmed: 33986431
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
J Am Soc Nephrol. 2021 Sep;32(9):2153-2158
pubmed: 34135083
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
MMWR Morb Mortal Wkly Rep. 2021 May 07;70(18):674-679
pubmed: 33956782
Microbiol Spectr. 2021 Sep 3;9(1):e0024721
pubmed: 34190591
Lancet Reg Health Eur. 2021 Oct;9:100178
pubmed: 34318288
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
Transplantation. 2021 Nov 1;105(11):e265-e266
pubmed: 34310531
J Clin Microbiol. 2021 Jun 18;59(7):e0038821
pubmed: 33827901
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Lancet. 2021 Mar 27;397(10280):1178-1181
pubmed: 33640037
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Ann Intern Med. 2021 Sep;174(9):1330-1332
pubmed: 34125572

Auteurs

Julien Marlet (J)

INSERM U1259, Université de Tours et CHRU de Tours, 37000 Tours, France.
Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, 37000 Tours, France.

Philippe Gatault (P)

Transplantation rénale-Immunologie clinique, CHRU de Tours, 37000 Tours, France.

Zoha Maakaroun (Z)

Centre de vaccination, CHRU de Tours, 37000 Tours, France.
Service de médecine pédiatrique, CHRU de Tours, 37000 Tours, France.

Hélène Longuet (H)

Transplantation rénale-Immunologie clinique, CHRU de Tours, 37000 Tours, France.

Karl Stefic (K)

INSERM U1259, Université de Tours et CHRU de Tours, 37000 Tours, France.
Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, 37000 Tours, France.

Lynda Handala (L)

INSERM U1259, Université de Tours et CHRU de Tours, 37000 Tours, France.
Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, 37000 Tours, France.

Sébastien Eymieux (S)

INSERM U1259, Université de Tours et CHRU de Tours, 37000 Tours, France.
Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, 37000 Tours, France.
Plate-Forme IBiSA de Microscopie Electronique, Université de Tours and CHRU de Tours, 37000 Tours, France.

Emmanuel Gyan (E)

Hématologie et Thérapie Cellulaire, CHRU de Tours, 37000 Tours, France.

Caroline Dartigeas (C)

Hématologie et Thérapie Cellulaire, CHRU de Tours, 37000 Tours, France.

Catherine Gaudy-Graffin (C)

INSERM U1259, Université de Tours et CHRU de Tours, 37000 Tours, France.
Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, 37000 Tours, France.

Classifications MeSH